Grifola frondosa(Maitake)is traditionally valued for its health benefits,with polysaccharides being key bioactive components.This paper investigates a specific subfraction,Fraction D(GFP-D),evaluating its clinical eff...Grifola frondosa(Maitake)is traditionally valued for its health benefits,with polysaccharides being key bioactive components.This paper investigates a specific subfraction,Fraction D(GFP-D),evaluating its clinical effects and mechanisms in immune enhancement,adjunctive anti-tumor activity,and regulation of glucose/lipid metabolism.Three clinical trials were conducted.In an immune study,120 healthy volunteers(CD4+T cell count 500–1000 cells/μL)received 150 mg/day GFP-D for 8 weeks,resulting in significant increases in CD4+T cells(from 632±95 to 812±108 cells/μL,28.5%increase,within the physiological activation range),CD4+/CD8+ratio,NK cell activity,IL-2,and IFN-γ(all P<0.001 vs.placebo).An anti-tumor study with 80 advanced cancer patients(stratified by age,tumor stage,and histotype)showed that adding 1000 mg/day GFP-D to chemotherapy improved objective response rate(52.5%vs.30.0%,P=0.036,95%CI:1.02–3.87),one-year progression-free survival(55.8%vs.33.3%,P=0.022),and preserved immune parameters versus chemotherapy alone.A metabolic study in 90 type 2 diabetes patients found that 400 mg/day GFP-D for 12 weeks significantly lowered fasting glucose,HbA1c,total cholesterol,triglycerides,and LDL-C,while raising HDL-C(from 1.0±0.2 to 1.2±0.2 mmol/L,20%increase,supported by increased AMPK phosphorylation).Mechanistically,immune enhancement involves macrophage/dendritic cell activation via Dectin-1/TLR4 receptors(confirmed by increased receptor expression and downstream signaling molecules),promoting cytokine-driven T/NK cell responses.Anti-tumor effects stem from immunomodulation,direct induction of cancer cell apoptosis(via mitochondrial/caspase pathways,verified by increased Bax/Bcl-2 ratio and caspase-3 activation),and angiogenesis inhibition by downregulating VEGF.Metabolic benefits are linked to AMPK pathway activation in liver/muscle(confirmed by increased p-AMPK/AMPK ratio),enhancing glucose uptake and inhibiting gluconeogenesis/lipogenesis,alongside modulation of gut microbiota(increased Bifidobacterium and Lactobacillus abundance).All trials reported no severe adverse events related to GFP-D;liver/kidney function parameters(ALT,AST,creatinine,urea nitrogen)remained within normal ranges throughout the intervention.Collectively,GFP-D emerges as a multi-functional bioactive agent with substantial therapeutic potential.展开更多
Iron deficiency anemia affects approximately 1.62 billion people worldwide,yet traditional iron supplements present bioavailability limitations and gastrointestinal side effects.This randomized,double-blind clinical t...Iron deficiency anemia affects approximately 1.62 billion people worldwide,yet traditional iron supplements present bioavailability limitations and gastrointestinal side effects.This randomized,double-blind clinical trial investigated a novel Auricularia auricula polysaccharide-iron complex(AAPIC)compared with heme iron and ferrous glycinate in 180 iron-deficient adults receiving 30 mg elemental iron daily for 12 weeks.AAPIC achieved comparable hemoglobin improvements(from 98.3±8.7 to 126.5±9.2 g/L)to heme iron(from 97.8±9.1 to 128.3±8.6 g/L)and was significantly superior to ferrous glycinate(from 98.6±8.9 to 119.7±10.3 g/L;p<0.001).Iron absorption efficiency showed AAPIC at 23.7±4.2%,heme iron at 25.1±3.8%,and ferrous glycinate at 18.4±5.1%.Toxicological assessments revealed no hepatotoxicity,nephrotoxicity,or mutagenicity.Gastrointestinal adverse events occurred in 8.3%of AAPIC recipients versus 15.0%with ferrous glycinate and 10.0%with heme iron.The polysaccharide component facilitates iron transport through enhanced intestinal uptake mechanisms.AAPIC represents a promising,well-tolerated alternative with clinical efficacy comparable to established iron formulations.展开更多
文摘Grifola frondosa(Maitake)is traditionally valued for its health benefits,with polysaccharides being key bioactive components.This paper investigates a specific subfraction,Fraction D(GFP-D),evaluating its clinical effects and mechanisms in immune enhancement,adjunctive anti-tumor activity,and regulation of glucose/lipid metabolism.Three clinical trials were conducted.In an immune study,120 healthy volunteers(CD4+T cell count 500–1000 cells/μL)received 150 mg/day GFP-D for 8 weeks,resulting in significant increases in CD4+T cells(from 632±95 to 812±108 cells/μL,28.5%increase,within the physiological activation range),CD4+/CD8+ratio,NK cell activity,IL-2,and IFN-γ(all P<0.001 vs.placebo).An anti-tumor study with 80 advanced cancer patients(stratified by age,tumor stage,and histotype)showed that adding 1000 mg/day GFP-D to chemotherapy improved objective response rate(52.5%vs.30.0%,P=0.036,95%CI:1.02–3.87),one-year progression-free survival(55.8%vs.33.3%,P=0.022),and preserved immune parameters versus chemotherapy alone.A metabolic study in 90 type 2 diabetes patients found that 400 mg/day GFP-D for 12 weeks significantly lowered fasting glucose,HbA1c,total cholesterol,triglycerides,and LDL-C,while raising HDL-C(from 1.0±0.2 to 1.2±0.2 mmol/L,20%increase,supported by increased AMPK phosphorylation).Mechanistically,immune enhancement involves macrophage/dendritic cell activation via Dectin-1/TLR4 receptors(confirmed by increased receptor expression and downstream signaling molecules),promoting cytokine-driven T/NK cell responses.Anti-tumor effects stem from immunomodulation,direct induction of cancer cell apoptosis(via mitochondrial/caspase pathways,verified by increased Bax/Bcl-2 ratio and caspase-3 activation),and angiogenesis inhibition by downregulating VEGF.Metabolic benefits are linked to AMPK pathway activation in liver/muscle(confirmed by increased p-AMPK/AMPK ratio),enhancing glucose uptake and inhibiting gluconeogenesis/lipogenesis,alongside modulation of gut microbiota(increased Bifidobacterium and Lactobacillus abundance).All trials reported no severe adverse events related to GFP-D;liver/kidney function parameters(ALT,AST,creatinine,urea nitrogen)remained within normal ranges throughout the intervention.Collectively,GFP-D emerges as a multi-functional bioactive agent with substantial therapeutic potential.
文摘Iron deficiency anemia affects approximately 1.62 billion people worldwide,yet traditional iron supplements present bioavailability limitations and gastrointestinal side effects.This randomized,double-blind clinical trial investigated a novel Auricularia auricula polysaccharide-iron complex(AAPIC)compared with heme iron and ferrous glycinate in 180 iron-deficient adults receiving 30 mg elemental iron daily for 12 weeks.AAPIC achieved comparable hemoglobin improvements(from 98.3±8.7 to 126.5±9.2 g/L)to heme iron(from 97.8±9.1 to 128.3±8.6 g/L)and was significantly superior to ferrous glycinate(from 98.6±8.9 to 119.7±10.3 g/L;p<0.001).Iron absorption efficiency showed AAPIC at 23.7±4.2%,heme iron at 25.1±3.8%,and ferrous glycinate at 18.4±5.1%.Toxicological assessments revealed no hepatotoxicity,nephrotoxicity,or mutagenicity.Gastrointestinal adverse events occurred in 8.3%of AAPIC recipients versus 15.0%with ferrous glycinate and 10.0%with heme iron.The polysaccharide component facilitates iron transport through enhanced intestinal uptake mechanisms.AAPIC represents a promising,well-tolerated alternative with clinical efficacy comparable to established iron formulations.
